Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.

Sarepta stock dropped again Wednesday — extending a steep dive this year — after the Food and Drug Administration announced that it's investigating the deaths of two patients who received Sarepta ...

Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Sarepta Therapeutics is down 83.1% since the beginning of the year, and at $20.91 per share, it is trading 87.2% below its 52-week high of $163.85 from June 2024. Investors who bought $1,000 worth ...

Pharma Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients By Angus Liu Jun 16, 2025 10:58am ...

Investor Contact: Ian Estepan 617-274-4052 [email protected] Media Contacts: Tracy Sorrentino 617-301-8566 [email protected] Kara Hoeger 617-710-3898 [email protected] ...

Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a patient taking it died. The patient's death, reported by the biopharma firm ...

Sarepta Therapeutics (SRPT) reported that a patient with Duchenne muscular dystrophy taking its Elevidys treatment died of acute liver failure (ALF). Shares plunged more than 20% on the news.